Core Viewpoint - The company reported a significant decline in revenue and an increase in net loss for the first half of 2025, primarily due to strategic changes in its business operations [1] Financial Performance - Revenue decreased by 30.6% year-on-year to approximately 66.3 million [1] - Gross profit was approximately 32.1 million, reflecting a year-on-year decrease of 36.3% [1] - Net loss amounted to approximately 239 million, which is an increase of about 19.1% year-on-year [1] - Earnings per share showed a loss of 0.75 yuan [1] Strategic Decisions - The revenue decline was attributed to the company's cautious decision to terminate its agency partnership with the American skincare brand OMA due to macroeconomic policies and international environment impacts [1] - Resources are being reallocated towards the commercialization preparations of new products, CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam), which have received regulatory approval [1] - The new products are expected to have greater market potential and a higher return on investment, indicating a strategic shift aimed at long-term development [1]
科笛-B(02487)公布中期业绩 净亏损约2.39亿元 同比增加约19.1%